Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Japan’s MHLW to Add Seven Disorders to Federally Funded Intractable Diseases List

This article was originally published in PharmAsia News

Executive Summary

TOKYO - Japan's Ministry of Health, Labor and Welfare will include seven more diseases to its intractable disease list, which is eligible for federal research funding, effective April 2009

You may also be interested in...



Japan MHLW Quadruples Intractable Disease Budget, Adds Seven New Diseases

TOKYO - At a Feb. 10 meeting of its expert panel on orphan diseases held for the first time in more than six years, Japan's Ministry of Health, Labor and Welfare disclosed that it is planning to quadruple national budget outlays to ¥10 billion ($110 million) for the state's intractable disease research budget in fiscal 2009 and will designate seven new diseases qualifying for the project

PharmAsia News Business Bulletin

A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).

UsernamePublicRestriction

Register

ID036688

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel